AKT1 and colorectal carcinoma: Therefore, inhibiting the PI3K-AKT signaling pathway could be a promising therapeutic strategy for CRC, particularly in cases involving abundant S. flexneri, by targeting Nrg1, ERBB3, and their downstream signaling pathways.